Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Atypical hemolytic uraemic syndrome is caused by defects in the regulating factors in the alternative pathway of the complement system. Triggering can cause an uncontrolled complement activation with endothelial damage and thrombotic micro-angiopathy, especially in the kidneys. This can result in endstage renal failure. Complement activation during hemodialysis has been described as a result of contact between blood and the dialysis membrane. Our hypothesis is that patients with atypical hemolytic uraemic syndrome have a stronger complement activation during hemodialysis than patients with another underlying kidney disease. This could be a reason to treat patients with endstage renal failure due to atypical hemolytic uraemic syndrome preferentially with peritoneal dialysis instead of hemodialysis.
| Condition |
|---|
|
Atypical Hemolytic Uraemic Syndrome. |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease. |
- C3a-des-Arg measuring (as a marker of activation). [ Time Frame: at time 0, at 15 minutes, at 60 minutes and at 180 minutes ] [ Designated as safety issue: No ]
- white blood cell count [ Time Frame: before and after 15 minutes of hemodialysis ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
blood samples
| Estimated Enrollment: | 25 |
| Study Start Date: | August 2009 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
cases
patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
|
|
controls
patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
patients with endstage renal failure treated in het University Hospital of Ghent
Inclusion Criteria:
- cases: endstage renal failure due to atypical hemolytic uraemic syndrome treated with hemodialysis.
- controls: endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
Contacts and Locations| Contact: Rogier Caluwé, MD | rogier.caluwe@uzgent.be |
| Belgium | |
| University Hospital Ghent | Recruiting |
| Ghent, Belgium, 9000 | |
| Contact: Rogier Caluwé, MD rogier.caluwe@uzgent.be | |
| Principal Investigator: Raymond Vanholder, MD, PhD | |
| Sub-Investigator: Rogier Caluwé, MD | |
| Principal Investigator: | Raymond Vanholder, MD, PhD | University Hospital, Ghent |
More Information
Additional Information:
No publications provided
| Responsible Party: | University Hospital, Ghent |
| ClinicalTrials.gov Identifier: | NCT00930423 History of Changes |
| Other Study ID Numbers: | 2009/270 |
| Study First Received: | June 29, 2009 |
| Last Updated: | February 1, 2013 |
| Health Authority: | Belgium: Institutional Review Board |
Additional relevant MeSH terms:
|
Hemolytic-Uremic Syndrome Kidney Diseases Azotemia Hemolysis Uremia Urologic Diseases Anemia, Hemolytic |
Anemia Hematologic Diseases Thrombotic Microangiopathies Thrombocytopenia Blood Platelet Disorders Pathologic Processes |
ClinicalTrials.gov processed this record on May 22, 2013